Key Highlights

  • A finance VP at Omeros (OMER) exercised Options and sold shares at $20.95 under a trading plan, near the market price.
  • OMER combines a trailing P/E of 14.0 with a six-month return of +93.6% and is up about 370% over 52 weeks.
  • Cantor upgraded the stock to Overweight on Sept. 21 with a $22 target, citing a better-than-expected Yartemlea launch.

Omeros (NASDAQ:OMER) rose 3.8% to $20.90 in pre-market trading, near its 52-week high, after a finance vice president exercised options and sold stock at $20.95 under a pre-set trading plan. The biotech trades at just 14 times trailing Earnings after the launch of Yartemlea, the first FDA-approved therapy for a deadly stem-cell transplant complication, and Cantor just upgraded the stock.

Omeros pairs a low price-to-earnings ratio with strong six-month momentum, a rare mix in biotech, where richly valued growth stories are the norm. Omeros won FDA approval for narsoplimab, now sold as Yartemlea, the first therapy for transplant-associated thrombotic microangiopathy (TA-TMA), a serious complication of stem-cell transplants. The launch has gone better than expected: on Aug. 13, the stock jumped 26.6% after Q2 Revenue of $32.2 million beat forecasts, and Medicare granted Yartemlea a new-technology add-on payment, which helps hospitals cover the cost.

The insider sale was made under a Rule 10b5-1 trading plan, which sets sales in advance, so it is generally seen as routine rather than a bearish signal.

Omeros (OMER) Trades Near Its High

OMER's 52-week range is $4.06 to $21.24, putting the stock within a few percent of its peak. The market Capitalization is about $1.46 billion. Biotech peers were mixed: Maze Therapeutics rose 1.8% and Xeris Biopharma was little changed.

OMER Technical Levels: Strong Trend With Room to Run

OMER trades above its 50-day Moving Average of about $15.80 and its 200-day of about $12.74, a strong uptrend on both time frames.

RSI is about 62.8. RSI measures recent gains versus losses on a 0 to 100 scale, and a reading in the low 60s shows solid momentum without being overbought, which leaves room for a breakout above the 52-week high.

Short interest is about 17.6% of shares outstanding. If the launch keeps beating expectations, that crowded short position could add fuel to a move higher.

Risks to Watch

Omeros has diluted shareholders, with shares outstanding up about 36% in a year, and free Cash Flow is about -$68.7 million. Europe's CHMP issued a negative opinion on its Marketing application about three months ago, limiting near-term international sales. Analysts rate OMER a Buy with an average target of about $27.50, roughly 32% above the current price.

Peers Moving on This News